TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

cited authors

  • Agarwal, Neeraj; Shore, Neal D.; Dunshee, Curtis; Karsh, Lawrence Ivan; Azad, Arun; Fay, Andre P.; Carles, Joan; Sullivan, Beth; Di Santo, Nicola; Elmeliegy, Mohamed; Lin, Xun; Quek, Ruben G. W.; Czibere, Akos; Fizazi, Karim

authors

Publication Date

  • February 20, 2020

webpage

published in

category

volume

  • 38

issue

  • 6